Generation Bio (GBIO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 4, 2025, with voting on four key proposals and other business as may arise.
Only stockholders of record as of April 7, 2025, are eligible to vote, with 67,013,359 shares outstanding.
Proxy materials are available online, and voting can be done via internet, phone, mail, or during the meeting.
Voting matters and shareholder proposals
Election of three Class II directors for terms expiring in 2028.
Ratification of Ernst & Young LLP as independent auditor for 2025.
Advisory (non-binding) vote on executive compensation (say-on-pay).
Approval of a reverse stock split at a ratio between 1-for-10 and 1-for-30, with the exact ratio and timing at the board's discretion.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of ten members divided into three staggered classes, with detailed biographies provided for all directors and nominees.
Majority of directors are independent; only the CEO is not considered independent.
Board committees include audit, talent (compensation), and nominating/governance, each with defined responsibilities and independent membership.
Board and committees met regularly in 2024, with high attendance.
Corporate governance guidelines and a code of business conduct and ethics are in place.
Latest events from Generation Bio
- Up to $600M in securities may be offered, including $237M via ATM sales through TD Cowen.GBIO
Registration Filing - Proxy seeks approval for director elections, auditor, executive pay, and a reverse stock split.GBIO
Proxy Filing - Key votes include director elections, auditor ratification, and a flexible reverse stock split.GBIO
Proxy Filing - Redosable in vivo gene editing and novel LNPs drive next-gen therapies for blood and liver diseases.GBIO
2024 Cantor Fitzgerald Global Healthcare Conference - Redosable genetic medicine platforms advance T cell, HSC, and hemophilia A programs.GBIO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 - ctLNP and iqDNA advances enable durable, re-dosable in vivo therapies for major diseases.GBIO
TD Cowen Genetic Medicines & RNA Summit - Selective LNP-siRNA delivery to T-cells targets autoimmune disease with strong preclinical data.GBIO
24th Annual Needham Virtual Healthcare Conference - Selective ctLNP siRNA delivery to T cells targets autoimmune disease, IND planned for 2H26.GBIO
TD Cowen 45th Annual Healthcare Conference - Selective siRNA delivery to T cells offers new hope for autoimmune disease treatment.GBIO
Jefferies Global Healthcare Conference 2025